In 310 adults with obesity or overweight without type 2 diabetes, oral once-daily elecoglipron gave estimated mean weight changes of -2·6% (5 mg) to -10·5% (75 mg, weekly titration) at 26 weeks vs -0·6% with placebo; adverse events 84–98% vs 84%.
RCTn = 310
Davies et al. Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial